Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Biliary Tract Neoplasms 2Advanced or Metastatic Solid Tumors 2Thymoma 1Solid Tumor 1Sarcoma 1Piebaldism 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Doxorubicin 14pembrolizumab 11Specimen Handling 11Magnetic Resonance Spectroscopy 10Biopsy 9Cyclophosphamide 8X-Rays 7Radiotherapy 7Nivolumab 7Ifosfamide 7Phantoms, Imaging 6Gemcitabine 6liposomal doxorubicin 5Temozolomide 5Radiation 5tazemetostat 4palbociclib 4Trabectedin 4Nuclear Medicine Department, Hospital 4Irinotecan 4Ipilimumab 4pazopanib 3larotrectinib 3fludarabine 3cabozantinib 3atezolizumab 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Proton Therapy 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × envafolimab × 90 days × Clear all
NCT05941325 2026-05-14

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Shanghai 6th People's Hospital

Phase 2 Suspended
20 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡